AzTrials
AzTrials

Mood DisorderNCT00025935

Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder

An observational study of Mood Disorder, run by National Institute of Mental Health (NIMH) at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study seeks to learn more about the symptoms of severe mood dysregulation in children and adolescents ages 7-17. Children and adolescents with severe mood dysregulation (SMD) display chronic anger, sadness, or irritability, as well as hyperarousal (such as insomnia, distractibility, hyperactivity) and extreme… Read more about this study

Who is it for?
Ages 7 to 85 years
Conditions the study is for
Mood Disorder
What is being tested?
Lithium
How many people
2,350 participants
Where
1 siteUnited States
Study dates
1 Jan 2002to not given
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 to 85 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: There are 6 separate populations being studied in this protocol: 1.Children and adolescents between the ages of 7-17 years old who meet criteria for DMDD or subthreshold DMDD. 2.Parents of children and adolescents, who meet criteria for DMDD or subthreshold DMDD and are enrolled in 02-M-0021, and are 25-85 years old will be studied. 3.Healthy volunteer children and adolescents between the ages of 7-17 years old. 4.Healthy volunteer adults between the ages of 18-25 years old. 5.Children and adolescents between the ages of 12-17 years old who meet criteria for major depressive disorder (MDD). 6.Children and adolescents between the ages of 8-17 years who meet criteria for attention-deficit /hyperactivity disorder (ADHD) who do not have a mood disorder.

Who may be able to join

  • Inclusion criteria for children with DMDD, subthreshold DMDD:
  • 1.1.1 Ages 7-17 at the time of recruitment; will be followed in the longitudinal component of the study until age 25.
  • 1.1.2 Abnormal mood (specifically, anger, sadness, and/or irritability), present at least half of the day most days (or at least half the day at least one day per week for subthreshold), and of sufficient severity to be noticeable by people in the child's environment (e.g. parents/caregivers, teachers, peers).
  • 1.1.3 Compared to his/her peers, the child exhibits markedly increased reactivity to negative emotional stimuli that is manifest verbally or behaviorally. For example, the child responds to frustration with extended temper tantrums (inappropriate for age and/or precipitating event), verbal rages, and/or aggression toward people or property. Such events occur, on average, at least three times a week. For subthreshold DMDD such tantrums occur on average at least once per month.
  • 1.1.4 The symptoms in # 1.1.2, and 1.1.3 above are currently present and have been present for at least 12 months without any symptom-free periods exceeding three months.
  • 1.1.5 The onset of symptoms must be prior to age 10 years.
Show all 41Show fewer
  • 1.1.6 For DMDD the symptoms are severe in at least in one setting (e.g. violent outbursts, assaultiveness at home, school, or with peers) and at least mild (distractibility, intrusiveness) in a second setting. For subthreshold DMDD, there must be evidence of impairment causing distress to the child or to those around him/her in at least one setting.
  • Caregivers of children and adolescents with DMDD or subthreshold DMDD enrolled in 02-M-0021
  • 2.1.1. Are capable of performing behavioral tasks and/or scanning.
  • 2.1.2. Speaks English
  • Healthy Volunteer (Control) Children
  • 3.1.1. Control subjects will be group matched to the patients.
  • 3.1.2. Have an identified primary care physician.
  • 3.1.3. Speaks English
  • Healthy Volunteer Adults
  • 4.1.1 Control subjects will be group matched to the patients.
  • 4.1.2. They will have normal physical and neurological examinations by history or checklist
  • 4.1.3. Have an identified primary care physician.
  • 4.1.4 Speaks English
  • Children with Major Depressive Disorder (MDD) Inclusion criteria (all must be met):
  • 5.1.1 Ages 11-17 at the time of recruitment; will be followed in the longitudinal component of the study until age 25.
  • 5.1.2. DSM-IV or DSM-5 Major Depressive Disorder
  • 5.1.2.1 Five or more of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure.
  • 5.1.2.1.1 Depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., feeling sad, blue, "down in the dumps," or empty) or observation made by others (e.g., appears tearful or about to cry). (In children and adolescents, this may present as an irritable or cranky, rather than sad, mood.)
  • 5.1.2.1.2 Markedly diminished interest or pleasure in all, or almost all, activities every day, such as no interest in hobbies, sports, or other things the person used to enjoy doing.
  • 5.1.2.1.3. Significant weight loss when not dieting or weight gain (e.g., a change of more than 5 percent of body weight in a month), or decrease or increase in appetite nearly every day.
  • 5.1.2.1.4. Insomnia (inability to get to sleep or difficulty staying asleep) or hypersomnia (sleeping too much) nearly every day
  • 5.1.2.1.5. Psychomotor agitation (e.g., restlessness, inability to sit still, pacing, pulling at clothes or clothes) or retardation (e.g., slowed speech, movements, quiet talking) nearly every day
  • 5.1.2.1.6. Fatigue, tiredness, or loss of energy nearly every day (e.g., even the smallest tasks, like dressing or washing, seem difficult to do and take longer than usual).
  • 5.1.2.1.7. Feelings of worthlessness or excessive or inappropriate guilt nearly every day (e.g., ruminating over minor past failings).
  • 5.1.2.1.8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (e.g. appears easily distracted, complains of memory difficulties).
  • 5.1.2.1.9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideas without a specific plan, or a suicide attempt or a specific plan for committing suicide
  • 5.1.2.1.10 Symptoms cause clinically significant distress or impairment in social, occupational/academic, or other important areas of functioning.
  • 5.1.2.1.11. The episode is not attributable to the physiological effects of a substance or to another medical condition.
  • 5.1.3. Youth with MDD who are continuing in research as adults must also be receiving psychiatric care for their MDD, if it is ongoing
  • Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
  • 6.1.1. Age 8-17
  • 6.1.2. Currently meets DSM-IV or DSM-5 criteria for ADHD
  • 6.1.3. Subjects with other primary psychiatric disorders including anxiety disorders, dysthymic disorder, past major depression, oppositional defiant disorder, tic disorders, and the learning, communication, and elimination disorders may be accepted
  • 6.1.4. Have an identified primary care physician.
  • 6.1.5. Speaks English

Who cannot join

  • 1.3 Exclusion criteria for those with DMDD:
  • 1.3.1 The individual exhibits any of these cardinal bipolar symptoms:
  • 1.3.1.1 Elevated or expansive mood
  • 1.3.1.2 Grandiosity or inflated self-esteem
  • 1.3.1.3 Decreased need for sleep
  • 1.3.1.4 Increase in goal-directed activity (this can result in the excessive involvement in pleasurable activities that have a high potential for painful consequences)
Show all 45Show fewer
  • 1.3.1.5. Has BD symptoms in distinct periods lasting more than 1 day.
  • 1.3.2. Meets criteria for schizophrenia, schizophreniform disorder, schizoaffective illness, PDD, or PTSD.
  • 1.3.3. IQ< 70
  • 1.3.4. The symptoms are due to the direct physiological effects of a drug of abuse, or to a general medical or neurological condition.
  • 1.3.5. Currently pregnant or lactating
  • 1.3.6. Meets criteria for alcohol or substance abuse with the last three months
  • 2. Exclusion of caregivers of children and adolescents with DMDD or subthreshold DMDD
  • 2.1 Have an I.Q. < 70
  • 2.2 Have any serious medical condition or condition that interferes with participation
  • 3.2 Healthy Volunteer (Control) Children:
  • 3.2.1. I.Q. < 70;
  • 3.2.2. Any serious medical condition or condition that interferes with fMRI or MEG/EEG scanning, or fNIRS, pregnant or lactating;
  • 3.2.3. Past or current diagnosis of any anxiety disorder (panic disorder, GAD, Separation Anxiety Disorder, Social Phobia), mood disorder (manic or hypomanic episode, major depression), OCD, PTSD, Conduct Disorder, psychosis, current suicidal ideation, Tourette Disorder, Autism Spectrum Disorder or ADHD.
  • 3.2.4. Substance abuse within two months prior to study participation or present substance abuse
  • 3.2.5. History of sexual abuse.
  • 3.2.6. Parent or sibling with Bipolar Disorder, recurrent MDD, or any disorder with psychosis.
  • 4.2 Healthy Volunteer Adults:
  • 4.2.1. IQ< 70
  • 4.2.2. Pregnant
  • 4.2.3. Any past or current history of Bipolar Disorder (any manic or hypomanic episode), recurrent MDD, or any disorder with psychosis
  • 5.3 Exclusion criteria for those with MDD:
  • 5.3.1 The individual exhibits any of these cardinal bipolar symptoms:
  • 5.3.1.1 Elevated or expansive mood
  • 5.3.1.2 Grandiosity or inflated self-esteem
  • 5.3.1.3 Decreased need for sleep
  • 5.3.1.4 Increase in goal-directed activity (this can result in the excessive involvement in pleasurable activities that have a high potential for painful consequences)
  • 5.3.1.5. Has BD symptoms in distinct periods lasting more than 1 day.
  • 5.3.2. Meets criteria for schizophrenia, schizophreniform disorder, schizoaffective illness, PDD, or PTSD.
  • 5.3.3. IQ< 70
  • 5.3.4. The symptoms are due to the direct physiological effects of a drug of abuse, or to a general medical or neurological condition.
  • 5.3.5. Currently pregnant or lactating
  • 5.3.6. Meets criteria for alcohol or substance abuse with the last three months
  • 6.2. Exclusion criteria for those with ADHD:
  • 6.2.1. IQ<70
  • 6.2.2. Pregnancy
  • 6.2.3. Ongoing medical illness or neurological disorder other than ADHD
  • 6.2.4. Any condition that would interfere with the participants' ability to perform research tasks
  • 6.2.5. Current Major Depression
  • 6.2.6. Any past or present manic or hypomanic episode

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Melissa A Brotman, Ph.D. contact

(301) 435-6645

melissa.brotman@nih.gov

United States1 site, 1 recruiting

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892

    For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR), 800-411-1222 ext. TTY dial 711, ccopr@nih.gov

    Recruiting

Other trials in United States

About this study

Official title: Characterization and Pathophysiology of Severe Mood and Behavioral Dysregulation in Children and Youth

This study seeks to learn more about the symptoms of severe mood dysregulation in children and adolescents ages 7-17. Children and adolescents with severe mood dysregulation (SMD) display chronic anger, sadness, or irritability, as well as hyperarousal (such as insomnia, distractibility, hyperactivity) and extreme responses to frustration (such as frequent, severe temper tantrums). Researchers will describe the moods and behaviors of children with these symptoms and use specialized testing and brain imaging to learn about the brain changes associated with this disorder.

Read the detailed description

Objective:

Irritability is a common and impairing clinical presentation in youth. Despite its significant public health impact, the clinical course and pathophysiology of irritability remains poorly understood. Chronic and severe irritability is the primary symptom of the new DSM-5 diagnosis, disruptive mood dysregulation disorder (DMDD), is an associated symptom of other pediatric disorders including Attention-Deficit/Hyperactivity Disorder (ADHD), and can be a clinical precursor to Major Depressive Disorder (MDD) and anxiety disorders. In addition, irritability is a trait distributed continuously in youth, thereby fitting well within the National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC) initiative.

Clinically impairing irritability in children and adolescents began to gain more attention as interest grew in the diagnosis of pediatric bipolar disorder. Beginning in the 1990s, child psychiatry researchers suggested that while pediatric bipolar disorder can present with distinct episodes of mania or hypomania as in adults, the more typical pediatric presentation was chronic, severe irritability and hyperarousal symptoms. However, data collected under this protocol comprise a series of longitudinal, family, behavioral, and pathophysiological studies that differentiated classically defined episodic pediatric bipolar disorder from chronic irritability without distinct manic or hypomanic episodes. These findings are consistent with reports from other groups and meta-analyses.

Among the several strands of research designed to differentiate pediatric bipolar disorder from chronic irritability, longitudinal studies provide the strongest evidence that these two phenotypes are distinct. Children with chronic irritability are at elevated risk for later depression, but not manic episodes. Thus, youth with MDD (with and without prior DMDD) are an important comparison group to explore, and we are examining the developmental trajectory, phenomenology, behavioral correlates, and underlying neural mechanisms of chronic irritability and MDD in youth. Further, because irritability and ADHD symptoms are highly comorbid in youth, participants with ADHD are an important comparison group in our work on irritability.

The current translational model of irritability emphasizes the role of abnormal threat and reward processing, but also underlines the relevance of environmental factors in the emergence and maintenance of irritability. More precisely, it is assumed that irritable children experience environments, where rewards and punishments are inconsistently delivered leading to unintentional reinforcement of disruptive behavior through the parents. Reasons for this inconsistent parent behavior could be manifold spanning instrumental learning deficits and exaggerated responses to threat and frustrative non-reward in the parents themselves as well as lack of knowledge regarding learning principles and increased levels of stress. These factors might contribute to instrumental-learning deficits in the children increasing frequency and intensity of temper outbursts. Heightened levels of chronic irritability, another symptom of DMDD, might be more associated with features of the parent-child interaction. There is a rich literature within the framework of attachment theory showing that behavior of children with anxious-resistant insecure attachment is characterized by a general angry tone and is also associated with increased amygdala responses to negative social scenes. In addition, it was also shown that highly irritable infants are less sociable in terms of being less responsive and more fearful towards others and displaying an angry emotional tone in general as toddlers when they had been insecurely attached and more sociable when they had been securely attached. Adding another layer of complexity, it is also conceivable that inconsistent parent behavior diminishes parent's perceived trustworthiness. This could be of relevance as recent studies showed that persons are less willing to delay rewards - an action bound to increase levels of frustration - if their interaction partner is perceived as little reliable.

The overall goal is to gain a clearer understanding of the environmental factors contributing to irritability in order to inform treatment and improve the outcome for children. As part of this overall goal, we plan to collect information on numerous environmental factors. First, we plan to investigate parents of youth with DMDD enrolled in this study and subthreshold DMDD enrolled in this study in order to determine clinical, behavioral, neuropsychological, neurophysiological and neuroanatomical features of the parents that contribute to the symptomatology in the children and adolescents. Further, we plan to examine parent-child interaction and its influence on irritability observed in the youth. Second, we plan to investigate the role of environmental stressors on youth's irritability symptoms.

Study population:

There are 6 separate populations being studied in this protocol:

  1. Children and adolescents between the ages of 7-17 years old who meet criteria for DMDD or subthreshold DMDD.
  2. Caregivers of children and adolescents, who meet criteria for DMDD or subthreshold DMDD and are enrolled in 02-M-0021, and are 25-85 years old will be studied.
  3. Healthy volunteer children and adolescents between the ages of 7-17 years old.
  4. Healthy volunteer adults between the ages of 18-25 years old.
  5. Children and adolescents between the ages of 11-17 years old who meet criteria for major depressive disorder (MDD).
  6. Children and adolescents between the ages of 8-17 years who meet criteria for attention-deficit/hyperactivity disorder (ADHD) who do not have a mood disorder.

Design:

For children and adolescents with full or subthreshold DMDD, ADHD, and/or MDD, this study is an outpatient characterization and longitudinal follow-along design. Once determined to be eligible, individuals come for an initial assessment, and then return at varying intervals until age 25 for clinical interviews, behavioral tasks, structural and functional MRI, magnetoencephalography (MEG)/electroencephalography (EEG), and functional near-infrared spectroscopy (fNIRS).

For healthy volunteer children and adults this study is an outpatient cross-sectional study that includes clinical interviews, behavioral tasks, structural and functional MRI, magnetoencephalography (MEG)/electroencephalography (EEG), and functional near-infrared spectroscopy (fNIRS).

Outcome measures:

There are two primary outcome measures. First, this study will examine associations between irritability and clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables in individuals with full or subthreshold DMDD and/or MDD, ADHD, anxiety, and healthy volunteers. Second, this study will examine between-group differences in clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables in individuals with full or subthreshold DMDD and/or MDD, ADHD, anxiety, and healthy volunteers.

Conditions
Mood Disorder
Being tested
Lithium
Keywords
Neuroimaging, Mood Disorder, Conduct Disorder, Children and Adolescents, Affective Neuroscience, Natural History, Behavioral Dysregulation, Behavior, Children, Adolescent, Healthy Volunteer, HV, Normal Control
Medical subject headings
Mood Disorders, Conduct Disorder, Behavior

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LithiumDrug

Study groups in NCT00025935
Study groupRoleWhat they receive
Children/adolescents with ADHDChildren/adolescents with ADHD
Receives: Drug: Lithium
Children/Adolescents with DMDD or subthreshold DMDDChildren/Adolescents with DMDD or subthreshold DMDD
Receives: Drug: Lithium
Children/adolescents with MDDChildren/adolescents with MDD
Healthy volunteer adultsHealthy volunteer adults
Healthy volunteer children/adolescentsHealthy volunteer children/adolescents
Parents of children/adolescents with DMDD or subthreshold DMDDParents of children/adolescents with DMDD or subthresdhold DMDD

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To examine between-group differences in clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables

    Individuals with full or subthreshold DMDD and/or MDD, ADHD, anxiety (see protocol 00-M-0192), and healthy volunteers (see protocol 00-M-0198).

    Measured: 20 years

  2. To examine associations between irritability and clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables

    Individuals with full or subthreshold DMDD and/or MDD, ADHD, anxiety (see protocol 00-M-0192), and healthy volunteers (see protocol 00-M-0198).

    Measured: 20 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Nov 2001 (estimated)
  2. Study start1 Jan 2002

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
2,350 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00025935
Sponsor's protocol ID
020021
Other IDs
02-M-0021
Status last verified
21 Sep 2026
First submitted
31 Oct 2001
Last updated
23 Sep 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No individual participant data (IPD) will be shared.

Publications

  • Naim R, Pandya U, Shaughnessy S, German RE, Henry LM, Kircanski K, Brotman MA. Advancing the measurement of psychotherapy outcomes for youth with irritability using in vivo ecological momentary assessment: an exploratory observational study. Child Adolesc Ment Health. 2026 Feb;31(1):33-40. doi: 10.1111/camh.70039. Epub 2025 Oct 8.

    PubMed 41059673

  • Haller SP, Stoddard J, Cardenas SI, Dombek K, MacGillivray C, Botz-Zapp C, Bui HNT, Stavish CM, Kircanski K, Jones M, Brotman MA. Differentiating neural sensitivity and bias during face-emotion processing in youth: a computational approach. Soc Cogn Affect Neurosci. 2024 Jun 13;19(1):nsae034. doi: 10.1093/scan/nsae034.

    PubMed 38794949

  • McKay CC, Scheinberg B, Xu EP, Kircanski K, Pine DS, Brotman MA, Leibenluft E, Linke JO. Modeling Shared and Specific Variances of Irritability, Inattention, and Hyperactivity Yields Novel Insights Into White Matter Perturbations. J Am Acad Child Adolesc Psychiatry. 2024 Dec;63(12):1239-1250. doi: 10.1016/j.jaac.2024.02.010. Epub 2024 Mar 5.

    PubMed 38452811

  • Meigs JM, Kiderman M, Kircanski K, Cardinale EM, Pine DS, Leibenluft E, Brotman MA, Naim R. Sleepless nights, sour moods: daily sleep-irritability links in a pediatric clinical sample. J Child Psychol Psychiatry. 2024 Sep;65(9):1175-1183. doi: 10.1111/jcpp.13959. Epub 2024 Feb 14.

    PubMed 38355141

  • Tseng WL, Naim R, Chue A, Shaughnessy S, Meigs J, Pine DS, Leibenluft E, Kircanski K, Brotman MA. Network analysis of ecological momentary assessment identifies frustration as a central node in irritability. J Child Psychol Psychiatry. 2023 Aug;64(8):1212-1221. doi: 10.1111/jcpp.13794. Epub 2023 Mar 28.

    PubMed 36977629

  • Linke JO, Haller SP, Xu EP, Nguyen LT, Chue AE, Botz-Zapp C, Revzina O, Perlstein S, Ross AJ, Tseng WL, Shaw P, Brotman MA, Pine DS, Gotts SJ, Leibenluft E, Kircanski K. Persistent Frustration-Induced Reconfigurations of Brain Networks Predict Individual Differences in Irritability. J Am Acad Child Adolesc Psychiatry. 2023 Jun;62(6):684-695. doi: 10.1016/j.jaac.2022.11.009. Epub 2022 Dec 21.

    PubMed 36563874

  • Naim R, Shaughnessy S, Smith A, Karalunas SL, Kircanski K, Brotman MA. Real-time assessment of positive and negative affective fluctuations and mood lability in a transdiagnostic sample of youth. Depress Anxiety. 2022 Dec;39(12):870-880. doi: 10.1002/da.23293. Epub 2022 Nov 3.

    PubMed 36325887

  • Haller SP, Archer C, Jeong A, Jaffe A, Jones EL, Harrewijn A, Naim R, Linke JO, Stoddard J, Brotman MA. Changes in Internalizing Symptoms During the COVID-19 Pandemic in a Transdiagnostic Sample of Youth: Exploring Mediators and Predictors. Child Psychiatry Hum Dev. 2024 Feb;55(1):206-218. doi: 10.1007/s10578-022-01382-z. Epub 2022 Jul 6.

    PubMed 35794298

  • Zik J, Deveney CM, Ellingson JM, Haller SP, Kircanski K, Cardinale EM, Brotman MA, Stoddard J. Understanding Irritability in Relation to Anger, Aggression, and Informant in a Pediatric Clinical Population. J Am Acad Child Adolesc Psychiatry. 2022 May;61(5):711-720. doi: 10.1016/j.jaac.2021.08.012. Epub 2021 Aug 23.

    PubMed 34438022

  • Naim R, Goodwin MS, Dombek K, Revzina O, Agorsor C, Lee K, Zapp C, Freitag GF, Haller SP, Cardinale E, Jangraw D, Brotman MA. Cardiovascular reactivity as a measure of irritability in a transdiagnostic sample of youth: Preliminary associations. Int J Methods Psychiatr Res. 2021 Dec;30(4):e1890. doi: 10.1002/mpr.1890. Epub 2021 Aug 13.

    PubMed 34390050

  • Haller SP, Stoddard J, Botz-Zapp C, Clayton M, MacGillivray C, Perhamus G, Stiles K, Kircanski K, Penton-Voak IS, Bar-Haim Y, Munafo M, Towbin KE, Brotman MA. A Randomized Controlled Trial of Computerized Interpretation Bias Training for Disruptive Mood Dysregulation Disorder: A Fast-Fail Study. J Am Acad Child Adolesc Psychiatry. 2022 Jan;61(1):37-45. doi: 10.1016/j.jaac.2021.05.022. Epub 2021 Jun 17.

    PubMed 34147585

  • Naim R, Kircanski K, Gold A, German RE, Davis M, Perlstein S, Clayton M, Revzina O, Brotman MA. Across-subjects multiple baseline trial of exposure-based cognitive-behavioral therapy for severe irritability: a study protocol. BMJ Open. 2021 Mar 10;11(3):e039169. doi: 10.1136/bmjopen-2020-039169.

    PubMed 33692176

  • Scheinost D, Dadashkarimi J, Finn ES, Wambach CG, MacGillivray C, Roule AL, Niendam TA, Pine DS, Brotman MA, Leibenluft E, Tseng WL. Functional connectivity during frustration: a preliminary study of predictive modeling of irritability in youth. Neuropsychopharmacology. 2021 Jun;46(7):1300-1306. doi: 10.1038/s41386-020-00954-8. Epub 2021 Jan 21.

    PubMed 33479511

  • Linke JO, Abend R, Kircanski K, Clayton M, Stavish C, Benson BE, Brotman MA, Renaud O, Smith SM, Nichols TE, Leibenluft E, Winkler AM, Pine DS. Shared and Anxiety-Specific Pediatric Psychopathology Dimensions Manifest Distributed Neural Correlates. Biol Psychiatry. 2021 Mar 15;89(6):579-587. doi: 10.1016/j.biopsych.2020.10.018. Epub 2020 Nov 9.

    PubMed 33386133

  • Haller SP, Stoddard J, Pagliaccio D, Bui H, MacGillivray C, Jones M, Brotman MA. Computational Modeling of Attentional Impairments in Disruptive Mood Dysregulation and Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2021 May;60(5):637-645. doi: 10.1016/j.jaac.2020.08.468. Epub 2020 Nov 24.

    PubMed 33242544

Questions about this trial

What is this clinical trial studying?

An observational study of Mood Disorder, run by National Institute of Mental Health (NIMH) at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 41 inclusion and 45 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Melissa A Brotman, Ph.D. ((301) 435-6645, melissa.brotman@nih.gov), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To examine between-group differences in clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables (time frame: 20 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00025935, which also lists 31 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in